

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP 00/08837
10/088676

REC'D 15 NOV 2000

WIPO

PCT

EP00/8837

Bescheinigung

Certificate

Attestation

ESU

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00114649.7

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. Hatten

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

08/11/00

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 00114649.7
Demande n°:

Anmeldetag:
Date of filing: 07/07/00
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
MERCK PATENT GmbH
64293 Darmstadt
GERMANY

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
A novel member of the heparanase protein family

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

/

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

A novel member of the Heparanase protein family

Field of the Invention

This Invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „heparanase-2“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Summary of the Invention

The present invention relates to heparanase-2, in particular heparanase-2 polypeptides and heparanase-2 polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, autoimmune disorders, blood coagulation disorders, cancer, diabetes, ischemia, sepsis and stroke, hereinafter referred to as "diseases of the invention". In a further aspect, the

- 2 -

invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with heparanase-2 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate heparanase-2 activity or levels.

Description of the Invention

In a first aspect, the present invention relates to heparanase-2 polypeptides. Such polypeptides include:

(a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(c) an isolated polypeptide comprising the polypeptide sequence of SEQ ID NO:2;

(d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(e) the polypeptide sequence of SEQ ID NO:2; and

(f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2;

(g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the endoglucuronidase family of polypeptides. Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules of cell surfaces, basement membranes and the extracellular matrix (ECM). They play a major role in cell-cell and cell-extracellular matrix interactions. HSPGs have been reported to bind to a variety of different molecules like growth factors (e.g. fibroblast growth factors and platelet-derived growth factor), cytokines

- 3 -

(e.g. interleukin-2), extracellular matrix proteins (e.g. fibronectin, laminin, collagen), factors involved in blood coagulation (e.g. antithrombin III), and other proteins such as lipoproteins, DNA topoisomerases, and α -amyloid proteins (Kjellen, L. and Lindahl, U., *Annu. Rev. Biochem.* 60, 443-475 (1991); Wight, T.N. et al., *Curr. Opin. Cell Biol.* 4, 793-801 (1992)).

Binding of signalling molecules to HSPGs leads to their sequestration, thereby creating a localised, readily accessible depot of these bound molecules, which can easily be released upon degradation of HSPGs (Nissen, N. et al., *Biochem. J.* 338, 637-642 (1999)). Additionally HSPGs are important structural components of the ECM. In capillaries they are found mainly in the subendothelial basement membrane, where they support the vascular endothelium and stabilise the structure of the capillary wall. Expression of heparan sulfate (HS)-degrading endoglucuronidases, commonly called 'heparanases' (Nakajima, M. et al., *J. Biol. Chem.* 259, 2283-2290 (1984)), is found in blood borne cells and placental trophoblasts, reflecting their requirement for cell diapedesis activity associated with inflammatory processes or wound healing, and pregnancy, respectively (Vlodavsky, I. et al., *Invasion Metastasis* 12, 112-127 (1992); Goshen, R. et al., *Mol. Hum. Reprod.* 2, 679-684 (1996)).

Degradation of the HS moieties of HSPGs affects a great variety of biological processes. Of particular interest is the proposed function of heparanases in neoangiogenesis and metastasis, associated with malignant tumours. It has been shown that secreted heparanase activity induces endothelial mitogenesis (Folkman, J. et al., *Am. J. Pathol.* 13, 393-400 (1988); Ishai-Michaeli, R. et al., *Cell. Regul.* 1, 833-842 (1990)) and is directly correlating with the metastatic property of a number of human metastatic cell lines as well as specimens of human breast, colon and liver carcinomas (Nakajima, M. et al., *Science* 220, 611-613 (1983); Vlodavsky, I. et al., *Cancer Res.* 43, 2704-2711 (1983)).

While it is commonly acknowledged that heparanases play a crucial role in many important biological processes, it is not at all trivial to isolate this enzymatic activity, mainly because of instability of the enzymes and the difficulty in designing specific quantitative assays (Freeman, C. and Parish, C.R., *Biochem. J.* 325, 229-237 (1997)). Biochemical experiments identified so far three distinct groups of heparanase activities, with molecular weights of 137 kDa (Oosta, H.G.M. et al., *J. Biol. Chem.* 257,

- 4 -

11249-11255 (1982)), 50 kDa (Freeman, C. and Parish, C.R., *Biochem. J.* 330, 1341-13509 (1998)), and 32-40 kDa (Hoogewerf, A.J. et al., *J. Biol. Chem.* 270, 3268-3277 (1995)). Now, three independent groups report the successful cloning of the first mammalian heparanase gene representing the 50 kDa class (Vlodavsky, I. et al., *Nat. Medicine* 5, 793-802 (1999); Hulett, M.D. et al., *Nat. Medicine* 5, 803-809 (1999); Toyoshima M. and Nakajima M., *J. Biol. Chem.* 270, 24153-24160 (1999)). For the first time it is now possible to analyse molecularly this so far elusive enzyme class. RNA in situ show that this heparanase gene is preferentially expressed in highly metastatic mouse and human cell lines and in biopsy specimen of human tumours. Moreover, increased levels of heparanase were detected in sera (Nakajima, M. et al., *Science* 220, 611-613, (1983)) and urine of metastatic tumour-bearing animals and cancer patients (Vlodavsky, I. et al., *Nat. Medicine* 5, 793-802 (1999)). Transfection of low or non-metastatic tumour cell lines with the heparanase gene confers a high metastatic potential in experimental mice, resulting in an increased rate of mortality. On the contrary, treatment of experimental animals with heparanase inhibitors (e.g., non-anticoagulant species of low-molecular-weight heparin and polysulfated saccharides) considerably reduces the incidence of lung metastases by melanoma, Lewis lung carcinoma and mammary adenocarcinoma cells (Vlodavsky I. et al., *Invasion Metastasis* 14, 290-302 (1995), Parish, C.R. et al., *Int. J. Cancer* 40, 511-517 (1987)).

As it is generally accepted that heparanase activity plays a crucial role in many distinct biological processes, there is a clear need to identify further members of this protein family. This will help to develop tools for early detection and treatment of aberrant signalling processes, which are involved in various diseases such as (but not limited to) cancer metastasis, autoimmune disorders, or diabetes. While the first member of the 50 kDa class of heparanases has now been cloned, no further heparanase gene has been identified so far. The heparanase activity represented by the 32-40 kDa class was proposed to consist of a tetramer of four subunits each closely related to CXC chemokines (CTAP-III/NAP-2). However, the enzymatic activity of this complex results in the generation of disaccharides (Hoogewerf, A.J. et al., *J. Biol. Chem.* 270, 3268-3277 (1995)), while typical heparanase activity generates characteristic large molecular weight fragments during the degradation of

- 5 -

the HS substrate (Toyoshima M. and Nakajima M., J. Biol. Chem. 270, 24153-24160 (1999)). Here we report the identification of a novel member of the heparanase protein family. It is represented by a single EST partially encoding a novel protein (heparanase-2) closely related to the 50 kDa heparanase gene.

The biological properties of the heparanase-2 are hereinafter referred to as "biological activity of heparanase-2" or "heparanase-2 activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of heparanase-2.

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are biologically active fragments that mediate the biological activity of heparanase-2, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that

07-07-2000

VV 17.17

VV 17.17 17.17

EP00114649.7

SPEC

- 6 -

contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

5 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from ~~genetically engineered~~ host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

10 In a further aspect, the present invention relates to heparanase-2 polynucleotides. Such polynucleotides include:

15 (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1;

(b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1;

20 (d) the isolated polynucleotide of SEQ ID NO:1;

(e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

25 (f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(h) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2;

(i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising a nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

- 8 -

(c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1;
or

(d) is the RNA transcript of the DNA sequence of SEQ ID NO:1;

and RNA polynucleotides that are complementary thereto.

5

10

15

20

25

30

The polynucleotide sequence of SEQ ID NO:1 shows homology with AF144325 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)). The polynucleotide sequence of SEQ ID NO:1 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2. The polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is related to other proteins of the endoglucuronidase family, having homology and/or structural similarity with AAD42342 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one heparanase-2 activity.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human bladder, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the

- 9 -

polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's

07-07-2000

EP00114649.7

SPEC

- 10 -

solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

- 11 -

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al. (ibid). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any

- 12 -

system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

- 13 -

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled heparanase-2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising heparanase-2 polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

- 14 -

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;

5 (b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

10 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

15 The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes
20 according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in
25 Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping
30 (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the

- 15 -

GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A.
 radiation hybrid map of the human genome. Gyapay G, Schmitt K,
 Fizames C, Jones H, Vega-Czarny N, Spillelt D, Muselet D, Prud'Homme
 JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To
 determine the chromosomal location of a gene using this panel, 93 PCRs
 are performed using primers designed from the gene of interest on RH
 DNAs. Each of these DNAs contains random human genomic fragments
 maintained in a hamster background (human / hamster hybrid cell lines).
 These PCRs result in 93 scores indicating the presence or absence of
 the PCR product of the gene of interest. These scores are compared
 with scores created using PCR products from genomic sequences of
 known location. This comparison is conducted at
<http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable
 tools for tissue expression studies. Such studies allow the determination of
 expression patterns of polynucleotides of the present invention which may
 give an indication as to the expression patterns of the encoded
 polypeptides in tissues, by detecting the mRNAs that encode them. The
 techniques used are well known in the art and include in situ hybridisation
 techniques to clones arrayed on a grid, such as cDNA microarray
 hybridisation (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*,
 Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques
 such as PCR. A preferred method uses the TAQMAN (Trade mark)
 technology available from Perkin Elmer. Results from these studies can
 provide an indication of the normal function of the polypeptide in the
 organism. In addition, comparative studies of the normal expression
 pattern of mRNAs with that of mRNAs encoded by an alternative form of
 the same gene (for example, one having an alteration in polypeptide coding
 potential or a regulatory mutation) can provide valuable insights into the role
 of the polypeptides of the present invention, or that of inappropriate
 expression thereof in disease. Such inappropriate expression may be of a
 temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in blood cells,
 cancer tissues, fetal liver, lymph nodes, placenta, spleen, trophoblast cells.

- 16 -

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "Immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a

- 17 -

mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of

- 18 -

chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Colligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a heparanase-2 activity in the mixture, and comparing the heparanase-2 activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al*, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and heparanase-2 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

- 19 -

Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and heparanase-2 gene. The art of constructing transgenic animals is well established. For example, the heparanase-2 gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or

07-07-2000

7-7-0 14:16

EP00114649.7

496151727191→

+49 89 23994

SPEC

- 20 -

5 injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

10 Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- 15
- (a) a polypeptide of the present invention;
 - 20 (b) a recombinant cell expressing a polypeptide of the present invention;
 - (c) a cell membrane expressing a polypeptide of the present invention; or
 - (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

25 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

5 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*,
if it occurs in nature, it has been changed or removed from its original
environment, or both. For example, a polynucleotide or a polypeptide
naturally present in a living organism is not "isolated," but the same
10 polynucleotide or polypeptide separated from the coexisting materials of
its natural state is "isolated", as the term is employed herein. Moreover,
a polynucleotide or polypeptide that is introduced into an organism by
transformation, genetic manipulation or by any other recombinant method
is "isolated" even if it is still present in said organism, which organism
may be living or non-living.

15 "Polynucleotide" generally refers to any polyribonucleotide (RNA) or
polydeoxribonucleotide (DNA), which may be unmodified or modified
RNA or DNA. "Polynucleotides" include, without limitation, single- and
double-stranded DNA, DNA that is a mixture of single- and double-
stranded regions, single- and double-stranded RNA, and RNA that is
20 mixture of single- and double-stranded regions, hybrid molecules
comprising DNA and RNA that may be single-stranded or, more typically,
double-stranded or a mixture of single- and double-stranded regions. In
addition, "polynucleotide" refers to triple-stranded regions comprising
RNA or DNA or both RNA and DNA. The term "polynucleotide" also
25 includes DNAs or RNAs containing one or more modified bases and
DNAs or RNAs with backbones modified for stability or for other reasons.
"Modified" bases include, for example, tritylated bases and unusual bases
such as inosine. A variety of modifications may be made to DNA and
RNA; thus, "polynucleotide" embraces chemically, enzymatically or
30 metabolically modified forms of polynucleotides as typically found in
nature, as well as the chemical forms of DNA and RNA characteristic of
viruses and cells. "Polynucleotide" also embraces relatively short
polynucleotides, often referred to as oligonucleotides.

35 "Polypeptide" refers to any polypeptide comprising two or more amino
acids joined to each other by peptide bonds or modified peptide bonds,

- 22 -

i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.

5 "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical ~~modification techniques that are well known in the art.~~ Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

10 Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.

15 Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment

20 of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation,

25 gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance,

30 Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646,

35 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

- 23 -

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

- 24 -

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

5 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic

regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

15 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

20 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

25 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being

- 25 -

compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

5 "Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of
10 the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

15 Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the
20 programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the
25 best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970).
30 GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4
35 for polypeptide sequences, respectively. Preferably, % Identities and similarities are determined when the two sequences being compared are optimally aligned.

- 26 -

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at ~~www.ncbi.nlm.nih.gov~~ and ~~FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).~~

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5

in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

5

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

10

15

20

25

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a \cdot (x_a \cdot I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in SEQ ID NO:1 or SEQ ID NO:2, respectively,

30

I is the Identity Index ,

\cdot is the symbol for the multiplication operator, and

- 28 -

in which any non-integer product of x_a and 1 is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, unrelated, fused genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-heparanase-2, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-heparanase-2 or fragments of heparanase-2, to improve pharmacokinetic properties of such a fusion protein when used for therapy and to generate a dimeric heparanase-2. The Fc-heparanase-2 DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding heparanase-2 or fragments thereof. In some uses it would be desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc part completely after expression.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

- 29 -

Claims

1. An isolated polypeptide selected from one of the groups consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;

5 (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

d) the polypeptide sequence of SEQ ID NO:2 and

10 (e) fragments and variants of such polypeptides in (a) to (d).

2. The isolated polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2.

15 3. The isolated polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2.

4. An isolated polynucleotide selected from one of the groups consisting of:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;

20 (b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

25 (d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

- 30 -

- (e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;
- 5 (f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

or a polynucleotide sequence complementary to said isolated polynucleotide

and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

10

5. An isolated polynucleotide as claimed in claim 4 selected from the group consisting of:

- (a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;
- (b) the isolated polynucleotide of SEQ ID NO:1;
- 15 (c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and
- (d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

20 6. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

25

8. A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the

- 31 -

production of said polypeptide and recovering the polypeptide from the culture medium.

9. A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of claim 1.

10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:

10 (a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

15 (b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;

20 (d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

25 (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

(f) producing said compound according to biotechnological or chemical standard techniques.

07-07-2000

VV IT.22

VVT/ VIT/ (411)

EP00114649.7

10. 2TV

V.

SPEC

- 32 -

Abstract

Heparanase-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing heparanase-2 polypeptides and polynucleotides in diagnostic assays.

5

- 33 -

SEQUENCE LISTING

<110> Merck Patent GmbH

5 <120> Novel heparanase

<130> HSPraseKDWS

<140>

10 <141>

<160> 2

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 1779

<212> DNA

<213> Homo sapiens

20

<220>

<221> CDS

<222> (1)..(1779)

25 <400> 1

atg agg gtg ctt tgt gcc ttc cct gaa gcc atg ccc tcc agc aac tcc 48
Met Arg Val Leu Cys Ala Phe Pro Glu Ala Met Pro Ser Ser Asn Ser
1 5 10 15

30 cgc ccc ccc gcg tgc cta gcc ccg ggg gct ctc tac ttg gct ctg ttg 96
Arg Pro Pro Ala Cys Leu Ala Pro Gly Ala Leu Tyr Leu Ala Leu Leu
20 25 30

35 ctc cat ctc tcc ctt tcc tcc cag gct gga gac agg aga ccc ttg cct 144
Leu His Leu Ser Leu Ser Ser Gln Ala Gly Asp Arg Arg Pro Leu Pro
35 40 45

40 gta gac aga gct gca ggt ttg aag gaa aag acc ctg att cta ctt gat 192
Val Asp Arg Ala Ala Gly Leu Lys Glu Lys Thr Leu Ile Leu Leu Asp
50 55 60

gtg agc acc aag aac cca gtc agg aca gtc aat gag aac ttc ctc tcc 240
Val Ser Thr Lys Asn Pro Val Arg Thr Val Asn Glu Asn Phe Leu Ser
65 70 75 80

45 ctg cag ctg gat ccg tcc atc att cat gat ggc tgg ctc gat ttc cta 288
Leu Gln Leu Asp Pro Ser Ile Ile His Asp Gly Trp Leu Asp Phe Leu
85 90 95

50 agc tcc aag cgc ttg gtg acc ctg gcc cgg gga ctt tcc ccc gcc ttt 336
Ser Ser Lys Arg Leu Val Thr Leu Ala Arg Gly Leu Ser Pro Ala Phe
100 105 110

55 ctg cgc ttc ggg ggc aaa agg acc gac ttc ctg cag ttc cag aac ctg 384
Leu Arg Phe Gly Gly Lys Arg Thr Asp Phe Leu Gln Phe Gln Asn Leu
115 120 125

60 agg aac ccg gcg aaa agc cgc ggg ggc ccg gcc ccg gat tac tat ctc 432
Arg Asn Pro Ala Lys Ser Arg Gly Gly Pro Gly Pro Asp Tyr Tyr Leu
130 135 140

07-07-2000

: 7- 7- 0 : 14-00

EP00114649.7

496151727191+

+49 89 23994465-440

SPEC

- 34 -

	aaa aac tat gag gat gac att gtt cga agt gat gtt gcc tta gat aaa	480
	Lys Asn Tyr Glu Asp Asp Ile Val Arg Ser Asp Val Ala Leu Asp Lys	
	145 150 155 160	
5	cag aaa ggc tgc aag att gcc cag cac cct gat gtt atg ctg gtg ctc	528
	Gln Lys Gly Cys Lys Ile Ala Gln His Pro Asp Val Met Leu Val Leu	
	165 170 175	
10	caa agg gag aag gca gct cag atg cat ctg gtt ctt cta aag gag caa	576
	Gln Arg Glu Lys Ala Ala Gln Met His Leu Val Leu Lys Glu Gln	
	180 185 190	
15	ttc tcc aat act tac agt aat ctc ata tta aca gcc agg tct cta gac	624
	Phe Ser Asn Thr Tyr Ser Asn Leu Ile Leu Thr Ala Arg Ser Leu Asp	
	195 200 205	
20	aaa ctt tat aac ttt gct gat tgc tct gga ctc cac ctg ata ttt gct	672
	Lys Leu Tyr Asn Phe Ala Asp Cys Ser Gly Leu His Leu Ile Phe Ala	
	210 215 220	
25	cta aat gca ctg cgt cgt aat ccc aat aac tcc tgg aac agt tct agt	720
	Leu Asn Ala Leu Arg Arg Asn Pro Asn Asn Ser Trp Asn Ser Ser Ser	
	225 230 235 240	
30	gcc ctg agt ctg ttg aag tac agc gcc agc aaa aag tac aac att tct	768
	Ala Leu Ser Leu Leu Lys Tyr Ser Ala Ser Lys Lys Tyr Asn Ile Ser	
	245 250 255	
35	tgg gaa ctg ggt aat gag cca aat aac tat cgg acc atg cat ggc cgg	816
	Trp Glu Leu Gly Asn Glu Pro Asn Asn Tyr Arg Thr Met His Gly Arg	
	260 265 270	
40	gca gta aat ggc agc cag ttg gga aag gat tac atc cag ctg aag agc	864
	Ala Val Asn Gly Ser Gln Leu Gly Lys Asp Tyr Ile Gln Leu Lys Ser	
	275 280 285	
45	ctg ttg cag ccc atc cgg att tat tcc aga gcc agc tta tat ggc cct	912
	Leu Leu Gln Pro Ile Arg Ile Tyr Ser Arg Ala Ser Leu Tyr Gly Pro	
	290 295 300	
50	aat att ggg cgg ccg agg aag aat gtc atc gcc ctc cta gat gga ttc	960
	Asn Ile Gly Arg Pro Arg Lys Asn Val Ile Ala Leu Leu Asp Gly Phe	
	305 310 315 320	
55	atg aag gtg gca gga agt aca gta gat gca gtt acc tgg caa cat tgc	1008
	Met Lys Val Ala Gly Ser Thr Val Asp Ala Val Thr Trp Gln His Cys	
	325 330 335	
60	tac att gat ggc cgg gtg gtc aag gtg atg gac ttc ctg aaa act cgc	1056
	Tyr Ile Asp Gly Arg Val Val Lys Val Met Asp Phe Leu Lys Thr Arg	
	340 345 350	
65	ctg tta gac aca ctc tct gac cag att agg aaa att cag aaa gtg gtt	1104
	Leu Leu Asp Thr Leu Ser Asp Gln Ile Arg Lys Ile Gln Lys Val Val	
	355 360 365	
70	aat aca tac act cca gga aag aag att tgg ctt gaa ggt gtg gtg acc	1152
	Asn Thr Tyr Thr Pro Gly Lys Lys Ile Trp Leu Glu Gly Val Val Thr	
	370 375 380	
75	acc tca gct gga ggc aca aac aat cta tcc gat tcc tat gct gca gga	1200

- 35 -

	Thr Ser Ala Gly Gly Thr Asn Asn Leu Ser Asp Ser Tyr Ala Ala Gly	
	385 390 395 400	
5	ttc tta tgg ttg aac act tta gga atg ctg gcc aat cag ggc att gat Phe Leu Trp Leu Asn Thr Leu Gly Met Leu Ala Asn Gln Gly Ile Asp	1248
	405 410 415	
10	gtc gtg ata ogg cac tca ttt ttt gac cat gga tac aat cac ctc gtg Val Val Ile Arg His Ser Phe Phe Asp His Gly Tyr Asn His Leu Val	1296
	420 425 430	
15	gac cag aat ttt aac cca tta cca gac tac tgg ctc tct ctc ctc tac Asp Gln Asn Phe Asn Pro Leu Pro Asp Tyr Trp Leu Ser Leu Leu Tyr	1344
	435 440 445	
20	aag cgc ctg atc ggc ccc aaa gtc ttg gct gtg cat gtg gct ggg ctc Lys Arg Leu Ile Gly Pro Lys Val Leu Ala Val His Val Ala Gly Leu	1392
	450 455 460	
25	cag cgg aag cca cgg cct ggc cga gtg atc cgg gac aaa cta agg att Gln Arg Lys Pro Arg Pro Gly Arg Val Ile Arg Asp Lys Leu Arg Ile	1440
	465 470 475 480	
30	tat gct cac tgc aca aac cac cac aac cac aac tac gtt cgt ggg tcc Tyr Ala His Cys Thr Asn His His Asn His Asn Tyr Val Arg Gly Ser	1488
	485 490 495	
35	att aca ctt ttt atc atc aac ttg cat cga tca aga aag aaa atc aag Ile Thr Leu Phe Ile Ile Asn Leu His Arg Ser Arg Lys Lys Ile Lys	1536
	500 505 510	
40	ctg gct ggg act ctc aga gac aag ctg gtt cac cag tac ctg ctg cag Leu Ala Gly Thr Leu Arg Asp Lys Leu Val His Gln Tyr Leu Leu Gln	1584
	515 520 525	
45	ccc tat ggg cag gag ggc cta aag tcc aag tca gtg caa ctg aat ggc Pro Tyr Gly Gln Glu Gly Leu Lys Ser Lys Ser Val Gln Leu Asn Gly	1632
	530 535 540	
50	cag ccc tta gtg atg gtg gac gac ggg acc ctc cca gaa ttg aag ccc Gln Pro Leu Val Met Val Asp Asp Gly Thr Leu Pro Glu Leu Lys Pro	1680
	545 550 555 560	
55	cgc ccc ctt cgg gcc ggc cgg aca ttg gtc atc cct cca gtc acc atg Arg Pro Leu Arg Ala Gly Arg Thr Leu Val Ile Pro Pro Val Thr Met	1728
	565 570 575	
60	ggc ttt tat gtg gtc aag aat gtc aat gct ttg gcc tgc cgc tac cga Gly Phe Tyr Val Val Lys Asn Val Asn Ala Leu Ala Cys Arg Tyr Arg	1776
	580 585 590	
	taa	1779
55	<210> 2 <211> 592 <212> PRT <213> Homo sapiens	
60	<400> 2	

- 36 -

Met Arg Val Leu Cys Ala Phe Pro Glu Ala Met Pro Ser Ser Asn Ser
1 5 10 15
Arg Pro Pro Ala Cys Leu Ala Pro Gly Ala Leu Tyr Leu Ala Leu Leu
20 25 30
5 Leu His Leu Ser Leu Ser Ser Gln Ala Gly Asp Arg Arg Pro Leu Pro
35 40 45
Val Asp Arg Ala Ala Gly Leu Lys Glu Lys Thr Leu Ile Leu Leu Asp
50 55 60
10 Val Ser Thr Lys Asn Pro Val Arg Thr Val Asn Glu Asn Phe Leu Ser
65 70 75 80
Leu Gln Leu Asp Pro Ser Ile Ile His Asp Gly Trp Leu Asp Phe Leu
85 90 95
Ser Ser Lys Arg Leu Val Thr Leu Ala Arg Gly Leu Ser Pro Ala Phe
100 105 110
15 Leu Arg Phe Gly Gly Lys Arg Thr Asp Phe Leu Gln Phe Gln Asn Leu
115 120 125
Arg Asn Pro Ala Lys Ser Arg Gly Gly Pro Gly Pro Asp Tyr Tyr Leu
130 135 140
20 Lys Asn Tyr Glu Asp Asp Ile Val Arg Ser Asp Val Ala Leu Asp Lys
145 150 155 160
Gln Lys Gly Cys Lys Ile Ala Gln His Pro Asp Val Met Leu Val Leu
165 170 175
Gln Arg Glu Lys Ala Ala Gln Met His Leu Val Leu Leu Lys Glu Gln
180 185 190
25 Phe Ser Asn Thr Tyr Ser Asn Leu Ile Leu Thr Ala Arg Ser Leu Asp
195 200 205
Lys Leu Tyr Asn Phe Ala Asp Cys Ser Gly Leu His Leu Ile Phe Ala
210 215 220
30 Leu Asn Ala Leu Arg Arg Asn Pro Asn Asn Ser Trp Asn Ser Ser Ser
225 230 235 240
Ala Leu Ser Leu Leu Lys Tyr Ser Ala Ser Lys Lys Tyr Asn Ile Ser
245 250 255
Trp Glu Leu Gly Asn Glu Pro Asn Asn Tyr Arg Thr Met His Gly Arg
260 265 270
35 Ala Val Asn Gly Ser Gln Leu Gly Lys Asp Tyr Ile Gln Leu Lys Ser
275 280 285
Leu Leu Gln Pro Ile Arg Ile Tyr Ser Arg Ala Ser Leu Tyr Gly Pro
290 295 300
40 Asn Ile Gly Arg Pro Arg Lys Asn Val Ile Ala Leu Leu Asp Gly Phe
305 310 315 320
Met Lys Val Ala Gly Ser Thr Val Asp Ala Val Thr Trp Gln His Cys
325 330 335
Tyr Ile Asp Gly Arg Val Val Lys Val Met Asp Phe Leu Lys Thr Arg
340 345 350
45 Leu Leu Asp Thr Leu Ser Asp Gln Ile Arg Lys Ile Gln Lys Val Val
355 360 365
Asn Thr Tyr Thr Pro Gly Lys Lys Ile Trp Leu Glu Gly Val Val Thr
370 375 380
50 Thr Ser Ala Gly Gly Thr Asn Asn Leu Ser Asp Ser Tyr Ala Ala Gly
385 390 395 400
Phe Leu Trp Leu Asn Thr Leu Gly Met Leu Ala Asn Gln Gly Ile Asp
405 410 415
Val Val Ile Arg His Ser Phe Phe Asp His Gly Tyr Asn His Leu Val
420 425 430
55 Asp Gln Asn Phe Asn Pro Leu Pro Asp Tyr Trp Leu Ser Leu Leu Tyr
435 440 445
Lys Arg Leu Ile Gly Pro Lys Val Leu Ala Val His Val Ala Gly Leu
450 455 460
60 Gln Arg Lys Pro Arg Pro Gly Arg Val Ile Arg Asp Lys Leu Arg Ile
465 470 475 480
Tyr Ala His Cys Thr Asn His His Asn His Asn Tyr Val Arg Gly Ser

- 37 -

				485					490					495			
	Ile	Thr	Leu	Phe	Ile	Ile	Asn	Leu	His	Arg	Ser	Arg	Lys	Lys	Ile	Lys	
				500					505					510			
5	Leu	Ala	Gly	Thr	Leu	Arg	Asp	Lys	Leu	Val	His	Gln	Tyr	Leu	Leu	Gln	
			515					520					525				
	Pro	Tyr	Gly	Gln	Glu	Gly	Leu	Lys	Ser	Lys	Ser	Val	Gln	Leu	Asn	Gly	
		530					535					540					
	Gln	Pro	Leu	Val	Met	Val	Asp	Asp	Gly	Thr	Leu	Pro	Glu	Leu	Lys	Pro	
	545					550					555					560	
10	Arg	Pro	Leu	Arg	Ala	Gly	Arg	Thr	Leu	Val	Ile	Pro	Pro	Val	Thr	Met	
				565					570						575		
	Gly	Phe	Tyr	Val	Val	Lys	Asn	Val	Asn	Ala	Leu	Ala	Cys	Arg	Tyr	Arg	
				580					585					590			

15

THIS PAGE BLANK (USPTO)
